A phase III trial of cariprazine as an adjunctive treatment to antidepressant therapy in patients with major depressive disorder

Trial Profile

A phase III trial of cariprazine as an adjunctive treatment to antidepressant therapy in patients with major depressive disorder

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 Aug 2016 New trial record
    • 05 Aug 2016 According to an Allergan and Richter joint media release, this is the third phase III trial of cariprazine in adjunctive MDD and the company expects that this trial with previous positive clinical trial will support the regulatory submissions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top